<?xml version="1.0" encoding="UTF-8"?>
<ack>
 <title>Declaration of interests</title>
 <p>IC has received research funding from Eli-Lilly, Janssen-Cilag, Sanofi Oncology, Merck Serono, and Novartis; participated on advisory boards for Sanofi Oncology, Eli-Lilly, Bristol-Myers Squibb, Merck Sharpe Dohme (MSD), Bayer, Roche, and Five Prime Therapeutics; and received honoraria from Taiho, Pfizer, Amgen, and Eli-Lilly. EAH has received research funding from Bristol-Myers Squibb, Celgene, Merck-Serono, and MSD; participated on advisory boards for Celgene and Janssen; and received speaker fees and travel expenses from Bristol-Myers Squibb, Roche, and Janssen and travel expenses from Takeda. SM has received honoraria from Roche and travel support from Gilead. NM has received conference support and participated on advisory boards for Roche. DC has received research funding from Amgen, AstraZeneca, Bayer, Celgene, Medimmune, Merck Serono, Merrimack, and Sanofi. All other authors declare no competing interests.</p>
</ack>
